Showing results (31-40 of 123) with videos related to
Sort By:
Pageof 13
Respiration; International Review of Thoracic Diseases|September 19, 2012
Clinical characteristics and outcomes of patients with clinically unsuspected pulmonary embolism versus patients with clinically suspected pulmonary embolismMichal Shteinberg, Miriam Segal-Trabelsy, Yochai Adir, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 20, 2022
Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feedingRaksha Jain, Alvit Wolf, Michal Molad, et al.The Israel Medical Association Journal : IMAJ|January 28, 2019
COPD Exacerbator Phenotype is Inversely Associated with Current Smoking But Not with Haptoglobin PhenotypeSagee Tal, Yochai Adir, Nili Stein, et al.European Respiratory Review : an Official Journal of the European Respiratory Society|October 30, 2024
Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospectsArietta Spinou, Annemarie L Lee, Brenda O'Neil, et al.Clinical Transplantation|June 26, 2012
The impact of fluoroquinolone resistance of Gram-negative bacteria in respiratory secretions on the outcome of lung transplant (non-cystic fibrosis) recipientsMichal Shteinberg, Yael Raviv, Jihad Bishara, et al.ERJ Open Research|November 11, 2021
4-week daily airway clearance using oscillating positive-end expiratory pressure <i>versus</i> autogenic drainage in bronchiectasis patients: a randomised controlled trialGalit Livnat, Naama Yaari, Nili Stein, et al.ERJ Open Research|August 29, 2017
Lung function and disease severity in cystic fibrosis patients heterozygous for <i>p.Arg117His</i>Michal Shteinberg, Damian G Downey, Diane Beattie, et al.European Respiratory Review : an Official Journal of the European Respiratory Society|September 18, 2024
Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic targetMarcus A Mall, Jane C Davies, Scott H Donaldson, et al.Frontiers in Pediatrics|January 5, 2024
Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platformKarin Yaacoby-Bianu, Malena Cohen-Cymberknoh, David Shoseyov, et al.BMC Pharmacology & Toxicology|October 20, 2022
Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patientsKarin Yaacoby-Bianu, Zeev Schnapp, Ilana Koren, et al.Pageof 13